Is Cures 2.0 really a thing?
If you’re like me, you probably still have stressful flashbacks of the two-year struggle to get 21st Century Cures, the sweeping biomedical innovation bill, across the finish line. From countless press releases to daily rumors about which bills were in and which were out to marathon hearing after marathon hearing … it never stopped.
Are we really going to do all that again?
That was the question I started asking a few weeks ago. And while the bill’s architects, Reps. Diana DeGette (D-Colo.) and Fred Upton (R-Mich.), are hellbent on making it a thing, lots of groups around town are skeptical it can really happen. I was struck, in particular, by the open skepticism from drug industry lobbyists who, over and over again, emphasized that drug pricing is taking up 100% of their time. Even if Cures 2.0 could include some very industry-friendly provisions, they said it would have to wait. For more on the drug industry’s complicated relationship with Cures 2.0, check out my story here.
Are we really going to do all that again?
That was the question I started asking a few weeks ago. And while the bill’s architects, Reps. Diana DeGette (D-Colo.) and Fred Upton (R-Mich.), are hellbent on making it a thing, lots of groups around town are skeptical it can really happen. I was struck, in particular, by the open skepticism from drug industry lobbyists who, over and over again, emphasized that drug pricing is taking up 100% of their time. Even if Cures 2.0 could include some very industry-friendly provisions, they said it would have to wait. For more on the drug industry’s complicated relationship with Cures 2.0, check out my story here.
No hay comentarios:
Publicar un comentario